AGM/EGMJun 9, 2026, 04:32 PM
Humacyte Stockholders Approve 550M Authorized Shares, Elect Directors
AI Summary
Humacyte, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to increase the number of authorized common stock from 350,000,000 to 550,000,000 shares. Additionally, stockholders elected three Class II directors, approved named executive officer compensation on an advisory basis, and ratified Pricewaterhouse Coopers LLP as the independent auditor for 2026. They also voted for an annual frequency for future advisory votes on executive compensation.
Key Highlights
- Stockholders approved increasing authorized common stock from 350,000,000 to 550,000,000 shares.
- The amendment to increase authorized shares was approved with 102,313,282 votes for.
- Three Class II directors were elected to serve until the 2029 annual meeting.
- Named executive officer compensation was approved on an advisory basis with 40,100,324 votes for.
- Stockholders approved an annual frequency for future advisory votes on executive compensation with 54,130,231 votes for.
- Pricewaterhouse Coopers LLP was ratified as the independent auditor for 2026 with 125,187,135 votes for.
- A quorum of 127,474,086 shares, representing 57.41% of outstanding common stock, was present.
Price Impact
More from HUMA